Continue to treat LUTS, ED as two separate entities

As we continue to debate and search for a common treatment for these two diseases, physicians should continue to treat these as two different entities as we have in the past.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria